The guideline explicitly says if a patient has ASCVD, HF, or CKD, “an SGLT2 inhibitors or GLP-1 receptor analogs with demonstrated benefit is recommended as part of the regimen independently of HbA1c” [189,190]. This evidence concerns the gene SLC5A2 and atherosclerosis.